Table 2.
League tables showing the results of the network meta-analysis comparing the effects of all drugs including odds ratios and 95% credible intervals
| IL-2 | ||||||
|---|---|---|---|---|---|---|
| 2.81 (0.38–29.92) | Obinutuzumab | |||||
| 3.71 (0.55–37.30) | 1.32 (0.50–3.51) | Rituximab | ||||
| 3.92 (0.60–38.84) | 1.40 (0.57–3.43) | 1.06 (0.52–2.15) | Belimumab | |||
| 4.24 (0.57–45.19) | 1.51 (0.48–4.74) | 1.13 (0.41–3.14) | 1.08 (0.41–2.76) | Anifrolumab | ||
| 5.76 (0.88–56.22) | 2.05 (0.82–5.23) | 1.55 (0.73–3.29) | 1.46 (0.76–2.82) | 1.36 (0.52–3.63) | Abatacept | |
| 6.16 (0.92–60.20) | 2.20 (0.83–5.84) | 1.66 (0.75–3.76) | 1.58 (0.75–3.26) | 1.47 (0.53–4.07) | 1.08 (0.50–2.32) | Ocrelizumab |
| 6.88 (1.13–64.29) | 2.46 (1.13–5.46) | 1.86 (1.07–3.27) | 1.76 (1.14–2.74) | 1.63 (0.71–3.85) | 1.20 (0.73–1.97) | 1.12 (0.62–2.00) Control |